

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/701,395	09/25/2001	Francis X. Cunningham JR.	P108172-00022	8945	
4372	7590 04/02/2003				
ARENT FOX KINTNER PLOTKIN & KAHN			EXAMINER		
1050 CONNE SUITE 400	CTICUT AVENUE, N.W	RAMIREZ, DELIA M			
	ON, DC 20036	<del></del>			
	, 20 2000		ART UNIT	PAPER NUMBER	
			1652		
			DATE MAILED: 04/02/2003	1)	

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES IT ARTMENT-OF-COMMERCE Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
09/201,395	9/25/2001	Cunningham et a	e.	P108172-00022
		j	Delia Ramirez	
			ART UNIT	PAPER
				11

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents and Trademarks**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Applicants are advised not to send the electronic form of the sequence listing to the 20231 zip code address for the USPTO. Instead, it is recommended that the disk containing the sequence listing be hand carried directly to the Examiner at the following location: USPTO, Technology Center 1600, 7th Floor, Crystal Mall 1, 1911 South Clark St., Arlington, VA 22202. For additional information in regard to CRF submissions, please contact Mark Spencer at (301) 308-4212.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez, Ph.D., whose telephone number is (703) 306-0288. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy can be reached on (703) 308-3804. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

REBECCA E. PROUTY
PRIMARY EXAMINER

1/0/17

The state of the s	mente a see for a common seem		-	
	Application No.	Applicant(s)		
Notice to Comply	09/701,395	CUNNINGHAM ET AL.		
, itolice to comply	Examiner	Art Unit		
	Delia M. Ramirez	1652		
NOTICE TO COMPLY WITH REQUIREMENT NUCLEOTIDE SEQUENCE AND/OR AMIN				
Applicant must file the items indicated below within the avoid abandonment under 35 U.S.C. § 133 (extension)				
The nucleotide and/or amino acid sequence disclosu for such a disclosure as set forth in 37 C.F.R. 1.821 -			ements	
1. This application clearly fails to comply with the directed to the final rulemaking notice published at the effective filing date is on or after July 1, 1998, 1998) and 1211 OG 82 (June 23, 1998).	at 55 FR 18230 (May 1, 1990)	, and 1114 OG 29 (May 15, 1990	). If	
2. This application does not contain, as a separate required by 37 C.F.R. 1.821(c).	te part of the disclosure on pa	per copy, a "Sequence Listing" as	i	
3. A copy of the "Sequence Listing" in computer r 37 C.F.R. 1.821(e).	readable form has not been su	bmitted as required by		
4. A copy of the "Sequence Listing" in computer computer readable form does not comply with the attached copy of the marked -up "Raw Sequence	e requirements of 37 C.F.R. 1.			
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
7. Other:				
Applicant Must Provide:  ☑ An initial or substitute computer readable form (C	CRF) copy of the "Sequence Li	sting".		
An initial or substitute paper copy of the "Sequen-	ce Listing", as well as an ame	ndment directing its entry into the		

- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY